We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Beximco Pharma | LSE:BXP | London | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.50 | 33.00 | 34.00 | 33.50 | 33.50 | 33.50 | 113,608 | 00:00:00 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/1/2022 12:15 | Dividend not paid in ii yet Good increase today! Long term hold for me | fegger | |
15/1/2022 14:53 | I'm looking back at that chart at 120p and thinking. Why didn't I reduce my holding? | 3800 | |
14/1/2022 20:52 | Suspect we might look back on this retrace and think, why oh why didn't we buy more..... | microscope | |
13/1/2022 20:05 | A five-day course of Beximco’s Bexovid costs around $190 at drug stores at Dhaka. At some pharmacies in Dhaka it immediately sold out. Sohag Babu, a salesman at Lazz Pharma, one of the largest drug chain shops in the capital, said the store had sold its supplies as soon as it received them: “It just came to the market two days ago. We immediately received queries from customers.” While Bangladesh is not experiencing a surge of COVID-19 infections now, a new viral wave is expected to hit the country in the next few months. The availability of the new drug raises hopes that the country would be able to save more people from the disease. | stav13 | |
13/1/2022 19:17 | Does seem ridiculous. I was trying to find the XD date, (not when credited). Wonder if it was this week which might explain a few short-sighted sellers. | microscope | |
13/1/2022 18:26 | I don't understand why this has pulled back. Now on ttm p/e of less than 11. Growth looks set to continue, and I think these are a bargain. I've been thinking of reducing my emerging market exposure, but not much else here I don't like | leopoldalcox | |
13/1/2022 17:46 | Anyone know when dividend will be paid? | neil1pat | |
05/1/2022 10:39 | SYME is about to multibag | charlescharliesback | |
04/1/2022 22:30 | US doubles orders of Pfizer's Paxlovid to 20 million... "Big order for Pfizer's antiviral pill It comes as the US doubled its order for Pfizer's oral COVID-19 antiviral treatment. The drugs maker and the White House said 20 million courses of Paxlovid would now be procured - with four million ready by the end of January..." Bodes well for BXP's generic version... "30 December 2021 BEXIMCO PHARMACEUTICALS LTD. Beximco Pharma introduces world's first generic version of Pfizer's Paxlovid, the first US FDA approved oral therapy for COVID-19 treatment" | someuwin | |
04/1/2022 09:14 | Difficult to buy any. | someuwin | |
03/1/2022 20:28 | Hmm... I'm still sitting on these... :o) A buyout would still be nice, hopefully for £3+. In the meantime more sitting... be interesting to see how much cash they might make from Bexovid.... £3 might come quicker. I like this share because I just leave it alone and it drifts up. So we have a 179p prediction and that was before the recent RNS. :o) GLA | greg the grinch | |
01/1/2022 09:38 | Yesterday the UK approved the Pfizer pill for those with weakened immune systems, and I'd expect to see a tidal wave of further approvals globally in the coming weeks to try and keep pace with Omicron, and any future, variants. Obviously producing the world's first generic version puts Beximco right at the forefront of the fight against Covid. Also great point about the likelihood of BXP producing a vaccine, toadhall. HNY all! :) | microscope | |
31/12/2021 12:31 | We have another iron in the fire to stimulate interest. Just wait till the Co announces a plan to produce vaccines (non Covid / and possibly Covid). See the 24 th Nov RNS. No smoke without fire. | toadhall1 | |
31/12/2021 10:19 | I'm sure India in particular, with its population of about 1.4 billion, will be casting glances in Beximco's direction. Given the huge problems India has had with the Delta variant, and the fact that they provided Beximco with many millions of vaccines, further co-operation between the two would seem a logical step. | microscope | |
31/12/2021 08:54 | Nice write-up in The Times Market Report this morning. Here is an extract: Beximco Pharmaceuticals quick off the mark with clone of Pfizer’s antiviral drug "It’s been quite a year for listed pharmaceutical companies. Many have been at the forefront of the fight against coronavirus, rushing to produce vaccines in record time and in turn helping reopen economies across the world. One of those is Beximco Pharmaceuticals. The first Bangladeshi company to float on London’s junior stock market in 2005 makes cheap versions of patented drugs for sale in some of the world’s poorest countries. Its shares, which are up just over 10 per cent on this time last year, got a further boost yesterday after it launched what it claimed to be the world’s first generic version of Pfizer’s Covid-19 treatment Paxlovid. Last week the US Food and Drug Administration approved Pfizer’s antiviral pill after it proved nearly 90 per cent effective in preventing hospital admissions and deaths in high-risk patients. Beximco said it plans to launch its own version in Bangladesh under the name Bexovid. The news sent the shares to a record high, closing up 2½p, or 2.3 per cent, at 111p." | jim208 | |
30/12/2021 15:17 | .....Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces the launch of the world's first generic version of Pfizer's COVID-19 treatment Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use) which was granted emergency use authorization (EUA) by the US FDA on 22 December 2021. Directorate General of Drug Administration (DGDA), Bangladesh, has today granted EUA for the oral antiviral drug to treat mild-to-moderate COVID-19 in adults and children of 12 years and above. This novel antiviral pill showed almost 90% efficacy in preventing hospitali z ations and deaths in high-risk patients, and recent data from Pfizer suggests the drug retains its effectiveness against the fast-spreading Omicron variant of the coronavirus. Beximco Pharma will market this product under the brand name Bexovid, initially in Bangladesh. | davebowler | |
30/12/2021 12:40 | What an announcement! World's first generic version of Pfizer pill. If this was a better known pharma market reaction would be off the scale. Quiet time generally for market news, hopefully we'll get very decent press coverage. Fantastic yield, chart breakout too, profitable and low enough p/e! For anybody who's not seen this.... | microscope | |
30/12/2021 11:14 | On dividend payment questions, the company did drop an RNS on Christmas Eve to say that it will be paid on or before the 20th January. My past experience is that it can take time to filter into accounts, so it may need some patience. | jim208 | |
30/12/2021 11:07 | great RNS today IMO. Hopefully, BXP can roll this out to other countries outside of Bangladesh. | mfhmfh | |
21/12/2021 16:20 | Sorry - Stocko's changed the payment date to 1/1/22 | podgyted | |
21/12/2021 16:16 | When is the dividend due to be paid - haven't rec'd mine yet | podgyted | |
10/12/2021 13:22 | Dave - thanks for that | cb7 | |
24/11/2021 21:03 | A small rise on today's vaccine media comment. Patience needed. Put in the drawer and come back late next year. | outsizeclothes.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions